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THE EFFICACY OF CHLORHEXIDINE GLUCONATE IN REDUCING 
VENTILATOR-ASSOCIATED PNEUMONIA 
 
FELICIA A.E. SMITH 
ABSTRACT 
Respiratory assistance devices bypass essential host defenses and allow these 
pathogens direct access to the lower respiratory tract and hinder these defense systems to 
effectively clear respiratory pathogens (1). Mechanical ventilation in the presence of 
dental plaque with respiratory pathogens has the potential to lead to ventilator-associated 
pneumonia (VAP). Ventilator-associated pneumonia is the leading cause of morbidity 
and mortality in intensive care units. VAP influences increasing need for medical 
treatment and hospital length of stay (LOS) (2-4). Lower respiratory tract infections 
(LRTI) have been found to be the most expensive site per infection with 13% of all 
infections accounting for 29% of the total recorded cost (5). 
The purpose of this systematic review is to perform a comprehensive literature 
search to identify published randomized clinical trials relating to the efficacy of 
chlorhexidine gluconate (CHX) oral rinse in preventing VAP. CHX has been identified as 
the “gold standard” to reduce the number of microorganisms. This review also addresses 
the importance of oral health and the increased risk of respiratory infections from 
colonization by harmful pathogens within the oral mucosa. Clinical trials relating to the 
hypothesis in question were evaluated using Consolidated Standards of Reporting Trials 
(CONSORT) checklist for validity. Quality and strength of each randomized clinical trial 
	  	   vii 
were evaluated based on the requirements of the Agency for Healthcare Research and 
Quality (AHRQ). Nine bibliographic databases, from 1965-2012 were used to conduct 
the literature inquiry.  Ten studies included populations greater than or equal to 18 years 
of age and admitted to the intensive care unit receiving mechanical ventilation. The 
patients were, ventilated due to either trauma, undergoing elective cardiothoracic surgery, 
or from some other form of surgery, at risk for VAP. 
In one study, CHX oral rinse decreased microbial colonization of the respiratory 
tract and hospital-acquired pneumonia (HAP) in patients who underwent open-heart 
surgery and were intubated less than 24 hours. Yet the difference was not significant in 
patients intubated more than 24 hours who had a higher amount of bacterial colonization 
(6). Modulation of oropharyngeal colonization by the use of oral chlorhexidine has 
reduced the number of ICU-acquired HAP in selected patient populations such as those 
undergoing coronary bypass grafting, but its routine use is not recommended until more 
data become available (7). Findings from several studies suggest a significant decrease in 
the incidence of total nosocomial respiratory infections and systemic antibiotic use in 
patients who underwent open heart and used a CHX oral rinse as compared with 
ventilator patients who did not use the rinse; there was also a 65% decrease (13% vs. 4%) 
in the overall nosocomial infection rate in the chlorhexidine group (7,8,9). Using 2% 
chlorhexidine solution presents the strongest evidence for decreasing VAP (10,11). From 
Scannapieco and colleagues’ study we can conclude that twice daily is not necessarily 
better than once daily, but maybe a four times daily regimen with 2% instead of 0.12% 
CHX does make a difference in reducing the incidence of VAP (12). 
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INTRODUCTION 
 
Epidemiology  
 The number of years of life lost annually in the United States because of 
nosocomial infections is estimated at 350,000 (13). The impact of infectious diseases on 
the nation’s health is evaluated on an estimated number of infections treated annually in 
United States hospitals (14). Despite the availability of antimicrobial agents, infections of 
the urinary tract, lower respiratory tract, and surgical wounds account for the bulk of 
infectious diseases treated in hospitals and the burden of hospital costs (14). Lower 
respiratory tract infections (LRTI) have been found to be the most expensive site per 
infection with 13% of all infections accounting for 29% of the total recorded cost (5). 
Eliminating healthcare-associated infections (HAI) has been identified as an essential 
priority in many hospitals especially with a decrease in government funding (15-17). 
 Healthcare-associated infections are associated with healthcare treatment facilities 
in any setting (e.g. hospitals, long-term care facilities, ambulatory settings, and home 
care) where a patient may become exposed and colonized with pathogens associated with 
the healthcare treatment (18,19). Hospital-acquired pneumonia (HAP) affects at least 
250,000 patients in U.S. acute care institutions each year and is associated with crude 
mortality of approximately 30% (20). Nosocomial infections are HAI that have a direct 
burden on the economy and are an important cause of mortality and morbidity in 
hospitals (14,21). Nosocomial infections are related to mortality; 9% of the infections 
reportedly caused death, 38% contributed to it, and 37% were not related to death; in 
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15% of these infections, the relationship of the infection to death could not be determined 
(22). A study of nosocomial infections in 42 hospitals in 1986 showed that 50% of all 
nosocomial infections lead to death (22). If 35 million patients are admitted each year to 
approximately 7,000 acute-case institutions in the United States, the number of 
nosocomial infections, assuming overall attack rates of 2.5%, 5%, or 10%, would be 
875,000, 1.75 million, and 3.5 million, respectively (23). During the mid-1990’s, 
researchers noticed a steady rate of nosocomial infections with approximately five to six 
hospital-acquired infections per 100 admissions; nosocomial infections contributed $4.5 
billion in hospital costs, and more than 88,000 deaths with approximately 1 death every 6 
minutes (23). The average cost of these infections was $1,255, ranging from $866 for 
surgical wound infections and $203 for urinary tract infections (5). The rate of 
nosocomial infections per 1,000 patient days increased 36%, from 7.2% in 1975 to 9.8% 
in 1995 because of a dynamic shift of the healthcare system translating to shorter 
inpatient hospitalization with a dramatic increase in the number of patients (14). 
 Pneumonia is an infection of the pulmonary parenchyma classified as an acute 
lung injury, and is a cause of morbidity and mortality in the United States and developing 
countries (24). Necrotizing pneumonia may progress to other complications such as 
bronchiectasis and parenchymal scarring leading to recurrent pneumonias (24).  In a 
study conducted by Langer et al., 23.2% of the 724 patients who received mechanical 
ventilation actually developed pneumonia (25). Healthcare-associated infections like 
bacterial pneumonia have accounted for the most frequent cause associated with 
healthcare infections with treatable clinical manifestations.  
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  In the past, pneumonia was typically classified as community-acquired 
pneumonia (CAP), hospital-acquired pneumonia (HAP), or ventilator-associated 
pneumonia (VAP) (24). The prevalence rate of community-acquired pneumonia ranges 
from 8 to 15 per 1000 persons per year, with infants and the elderly having the greatest 
risk for infection but not the highest rates (26). Higher rates of pneumonia have been 
found in men than in women and in African Americans versus Caucasians (26). The 
potential involvement of more virulent pathogens has led to a revised classification 
system in which infection is categorized as either CAP or healthcare–associated 
pneumonia (HCAP), with subcategories of HCAP including hospital-acquired pneumonia 
(HAP) and ventilator-associated pneumonia (VAP) (24). Even though CAP affects 
individuals in noninstitutionalized settings, whereas HCAP more often occurs in patients 
in a healthcare setting, more than 600,000 hospitalizations and 45,000 deaths annually are 
associated with CAP (9,19,24,27). In the United States, ~80% of the 4 million annual 
CAP cases are treated on an outpatient basis, and approximately 20% are treated in the 
hospital (24,26). Hospitalizations because of CAP cost $9-10 billion U.S. dollars 
annually (24,26).   
 Healthcare-associated pneumonia comprises the 15% of all HAI’s acquired in the 
medical intensive-care unit (ICU) (18,22,24,26). Nosocomial-hospital-acquired 
pneumonia (NHAP) is a subcategory of HCAP, and is among the most common 
infections in United States hospitals, with NHAP as the second most common infection 
worldwide (19,24). NHAP is an infection of the lung that a patient acquires in the 
hospital not related to the original admittance diagnosis (28). The crude mortality rate for 
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HAP may actually be as high as 30 to 70%, but many of these critically ill patients with 
HAP die of their underlying disease rather than pneumonia (18,29). Patients defined as 
having HAP have usually received some form of treatment such as antimicrobial agents, 
chemotherapy, or renal replacement therapy within 30 days before the onset of infection 
(19). HAP also includes patients who need emergency treatment and are hospitalized for 
2 or more days within the 90-day National Healthcare Safety Network surveillance 
protocol (9,19). 
  Nationwide statistics collected from U. S. hospitals between 1975-1976 reported a 
nosocomial infection rate among the 6,449 acute-care U.S. hospitals of 5.7 infections per 
100 admissions and the number of nosocomial infections of all types was just over 2.1 
million per year in the mid-1970s (24). An analysis was conducted on 200 consecutive 
hospitalizations in Columbia-Presbyterian Medical Center and Hackensack Hospital (30). 
When nosocomial infections were causally related or contributed to death, infection of 
the lower respiratory tract contributed to 60% of the fatal infections and was the leading 
cause of death from hospital-acquired infections (30).  
  According to the 1997 Centers for Disease Control and Prevention (CDC)  
Guidelines, NHAP, such as ventilator-associated pneumonia, is the sixth leading cause of 
morbidity and mortality in healthcare facilities across the nation despite hospital efforts to 
provide excellent quality care (22,26,27). The primary risk factor for the development of 
hospital-associated bacterial pneumonia is mechanical ventilation (MV) following 
intubation (with its requisite endotracheal intubation) (18). Patients receiving ventilatory 
support increase their risk of VAP by 1% per day of ventilation and account for 86% of 
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the cases of nosocomial pneumonia (31). VAP is defined as pneumonia occurring more 
than 48 hours after endotracheal intubation and initiation of MV, and the crude mortality 
rate ranging from 24 to 50% can reach 76% in some specific settings or when lung 
infection is caused by high-risk pathogens (3,25,32). 
  Ventilator-associated pneumonia is the leading cause of morbidity and mortality 
in intensive care units, influences up to 30% of hospital mortality hospital charges, and is 
a determinant of the increasing need for medical treatment and hospital length of stay 
(LOS) (2-4). Hospital length of stay may average around 7-9 days per patient with a 
median length of stay in the ICU averaging around 21 days (3,33,34). VAP produces a 2-
10 times greater probability of mortality for intensive care patients receiving ventilation 
compared to those patients who do not require mechanical ventilation (2,35,36). 
Prevalence estimates vary between 6 and 52 cases per 100 patients, with VAP, and an 
incidence of around 22.8% in patients receiving mechanical ventilation (24,37). This 
estimate may vary with certain population groups and microorganisms responsible for 
VAP, and do not reflect the reoccurrence of VAP in the same patient (24,32). Once a 
ventilated patient is transferred to a chronic care facility or home, the incidence of 
pneumonia drops significantly, especially in the absence of other risk factors for 
pneumonia (24). A large prospective cohort study conducted by Cook et al. focused on 16 
Canadian intensive care units and observed a higher risk of VAP in the subset of patients 
treated with MV. Of the 16 ICUs, 177 patients out of 1014 mechanically-ventilated 
patients developed VAP (38). Patients treated with continuous ventilation had 21 times 
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greater risk of acquiring VAP than patients who had been previously treated with 
continuous ventilatory support (39).  
 VAP is a common nosocomial infection that is associated with poor clinical and 
economic outcomes. Apart from death, the major complication of VAP is prolongation of 
mechanical ventilation, with corresponding increases in length of stay in the ICU. The 
muscle loss and general debilitation from an episode of VAP often require prolonged 
rehabilitation, and are associated with higher incidence of pulmonary infection. 
Sometimes elderly patients are unable to return to independent function and need nursing 
home care which adds a considerable financial burden (24,25). Regardless of the causal 
relationship between pneumonia and mechanical ventilation, the increased length of 
hospital stay as a result of VAP in the US has averaged an excess cost over the years.  In 
1982, the excess cost was approximately $1,255. A similar study in 1985 reported an 
average extra cost of $2,863 per patient with nosocomial pneumonia (NP) (5). By 1996, 
mean hospital admission and charges per patient have been estimated to be an additional 
$40,000 including out billed charges (18,40-42). For example, if hospital costs averaged 
only $500/day and excess stay due to pneumonia were limited to seven days, the direct 
cost of NP would be $1.1 billion annually (20). Comparative cost analysis is dependent 
on a wide variety of factors that differ from one country to another, including healthcare 
system, organization of the hospital and the ICU, and the possibility of patients being 
treated by private practitioners (42).  
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Etiology  
Time of onset is the most important variable risk factor in determining the 
prognosis of VAP. Other risk factors include duration of exposure to the healthcare 
environment, the causative microbial agents, a number of host factors, and treatment-
related factors (4,7,24,32). The two classifications identifying time of onset for VAP is 
either early-onset pneumonia (EOP) or late-onset pneumonia (LOP) (18). These 
categories are based on the time frame from intubation to the development of pneumonia 
(18,31,43). Early-onset VAP, usually less severe with a more favorable outcome and 
associated with antibiotic-sensitive organisms, occurs 48 to 96 hours after intubation and 
initiation of mechanical ventilation (31,32,43,44). If pneumonia develops 96 hours after 
the patient’s admission to an ICU or more than 48hours after intubation and initiation of 
mechanical ventilation, it is suggested that the patient has acquired LOP (18,44).  
Differences between early and late onset VAP are due to the different distribution 
of etiologic agents and the frequent administration of prior antimicrobial therapy (32). 
The pathogens responsible for causing the highest incidence of hospital-acquired fatality 
are aerobic, Gram-negative bacilli (GNB) (45). These pathogens are historically 
associated with an increased prevalence of nosocomial pneumonia in studies of critically 
ill and/or mechanically ventilated patients in intensive-care units (46). The most 
commonly encountered and potentially antibiotic-resistant Gram-negative bacteria 
associated with VAP are Pseudomonas aeruginosa, Acinetobacter species, 
Enterobacteriaceae (Proteus spp., Escherichia coli, Klebsiella spp.,), and Haemophilus 
influenzae (7,18,47,48). Twenty-four bacteriologic studies conducted on VAP patients, 
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analyzed by Chastre et al. confirmed that 58% of aerobic GNB were recovered from the 
controlled uncontaminated specimens (32). Due to prior hospitalization and use of 
antibiotics in many patients developing early-onset VAP prior to their transfer to the ICU, 
the most common pathogens associated with early-onset VAP, according to Ibrahim et al, 
were Pseudomonas aeruginosa (25.1%), Staphylococcus aureus (17.9%), and 
Enterobacter species (10.2%) (48). Late-onset VAP (5 days or more) more commonly 
involve antibiotic-resistant bacteria and multidrug-resistant (MDR) pathogens, and are 
associated with increased patient mortality and morbidity (7,18). Patients with high-risk 
pathogens (Pseudomonas aeruginosa, Acinetobacter spp., and Stenotrophomonas 
maltophilia) had a significantly higher hospital mortality rate (65%) in comparison with 
patients who developed late-onset VAP due to other microbes (31%) or patients without 
late-onset pneumonia (37%) (49). These pathogens were usually not present alone, so that 
VAP is considered a polymicrobial infection. Over the last decade or two, however, 
patients presenting to the hospital as outpatients with onset of pneumonia are now more 
commonly infected with multidrug-resistant (MDR) pathogens that have previously 
associated with hospital-acquired pneumonia (50). MDR pathogens are a matter of 
concern since they are associated with significantly greater attributable mortality than 
non-MDR pathogens (24). It is important to keep a low frequency of MDR pathogens 
among healthy people in order to prevent the likelihood of them developing VAP from 
these organisms, if hospitalized and ventilated (24). More recently, however, some 
investigators have reported that Gram-positive bacteria, such as methicillin-resistant 
Staphylococcus aureus (MRSA) or methicillin-sensitive S. aureus (MSSA), have become 
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increasingly more common in hospital settings (32). When a study compared Gram-
positive pneumonias, the VAP mortality due to MRSA was found in 86% of the cases 
with pneumonia with a relative risk of death equal to 20.7. However, mortality due to 
MSSA was found in 12% of the pneumonia cases (51,52). Hospital patients acquiring 
pneumonias due to other organisms, have a documented mortality rate of (55%), 
compared to the 87% mortality rate studied in patients with Pseudomonas aeruginosa and 
Acinetobacter spp. (32). Studies reporting on Pseudomonas pneumonia indicate that this 
organism accounts for 8.5% of all nosocomial infections, death rates of more than 80%, 
and an attack rate of 36 infections per 10,000 hospital discharges (32,53,54).  
Clinicians must clearly be aware of the different distribution patterns of etiologic 
agents associated with early-and late-onset VAP and consider them when administering 
prophylactic antimicrobial therapy to avoid inadequate therapy (32,48). In a prospective 
study that included 129 episodes of nosocomial pneumonia, responsible pathogens were 
compared according to whether the patients had received antimicrobial therapy before 
pneumonia. The onset rate of pneumonia caused by Gram-positive cocci or H.influenzae 
was significantly lower in patients who had received antibiotics, whereas the rate of 
pneumonia caused by P. aeruginosa was significantly higher (55). Potentially drug-
resistant bacteria are the most significant risk factor for VAP. For example, after prior use 
of broad-spectrum drugs such as the third generation cephalosporin, fluoroquinolone, 
and/or imipenem and 7 days of mechanical ventilation, MRSA, P. aeruginosa, A. 
baumannii, and/or S. maltophilia were found in 135 consecutive episodes of VAP (56).  
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Numerous fluctuations in the oral environment can influence many aspects of the 
initial colonization, maturation, and survival of microorganisms within oral plaque (57). 
It has been well established that Gram-negative bacilli play a major role in the 
relationship that exists between oropharyngeal colonization with GNB and nosocomial 
infections of the lower airways (58,59). Aerobic Gram-negative bacilli in pharyngeal 
cultures may be found infrequently in a healthy population that have or have not had a 
hospital exposure (18,58). The oropharynx is a non-sterile cavity, continuously colonized 
with facultative anaerobes and Gram-positive cocci; however, these organisms are 
considered part of the normal oropharyngeal flora (19,60). Actually all of the 
microorganisms, which comprise the microbiota in the human body, are naturally 
acquired from the environment and are considered part of our "normal" flora (19,57,61). 
Endogenous and exogenous factors influence the general environment and 
microenvironments in the oral cavity (62). Endogenous factors in the oral cavity are 
derived from the host, and they include: salivary proteins, glycoproteins, enzymes, 
teeth, pellicle, shedding mucous membrane, barrier functions of oral mucous 
membranes, humoral immune factors (salivary and serum antibody), cellular immune 
factors (e.g., lymphocytes, neutrophils, and cytokines), and protective factors (62). 
Exogenous infections resulting from transient bacteria are virulent and less well 
adapted to the human host (62). Pathogens causing exogenous infections typically do 
not require predisposing host conditions or unusual environmental alterations to exert 
pathogenic potential (62). Native bacteria in the oral cavity play an integral part in 
preventing colonization by, emergence of, exogenous pathogens (62).   
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Dental plaque consists of different species of bacteria that are not uniformly 
distributed, because different species colonize the tooth surface at different times and 
under different circumstances; this explains the versatility of plaque to proliferate in 
different environments (9,57,63,64). Dental surfaces provide the perfect opportunity for 
bacteria attach to surfaces of the host and form colonies on oral soft tissues such as the 
gingiva, tongue, cheeks, and alimentary tract (57).  The oral cavity of the host contains 
several types of surfaces, including keratinized and non-keratinized epithelium, and those 
of the teeth, which bacteria may colonize (61). Some bacteria may specifically require the 
presence of, or exhibit preferred attachment to, particular surfaces of the mouth. The 
development of bacterial plaque has been shown to involve the attachment of 
Streptococcus sanguis to the teeth, followed by Streptococcus mutans (S. mutans) (57). 
Other bacteria that may colonize the teeth include Streptococcus mitis, Actinomyces 
viscous, and Bacteroides gingivalis (24,57,61). Streptococcus mitis are usually found in 
high proportions on both buccal and tooth surfaces (61). The dorsal posterior aspect of 
the tongue harbors millions of organisms such as Streptococcus salivarius (57,61,65,66).  
  Mechanical ventilation in the presence of dental plaque containing respiratory 
pathogens has the potential to lead to ventilator-associated pneumonia (VAP). Biofilm 
formation in many cases precedes the development of VAP, and perhaps more 
importantly, represents a persistent source of organisms causing recurrent infections (67). 
A clean enamel surface is covered in a few seconds by an adsorbed layer of molecules 
comprising mainly glycoprotein from saliva, forming the acquired pellicle to which 
microorganisms initially adhere (19). A single bacterial species, or more than one 
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species, may aggregate on solid surfaces to form a biofilm composed of a slimy coat 
within a polysaccharide matrix (19). Alteration of the mucosal surface, destruction of the 
salivary film, and production of cytokines by the host defense system in response to 
bacterial invasion are the initial physiochemical and biochemical steps involved in the 
attachment of bacteria to solid surfaces and colonization by respiratory pathogens (19). 
Adhesion to the surfaces in the mouth is essential for the existence and proliferation of 
bacterial organisms (61). The primary colonizers, adhering directly to the acquired 
pellicle, such as streptococci and Actinomyces, are encased in an exopolysaccharide 
matrix (19,57,68). These undisturbed primary colonizers are eventually joined by 
secondary colonizers (57). Secondary colonizers synthesize protein adhesins that 
recognize receptors on primary colonizers (68). As bacteria proliferate, they synthesize 
extracellular matrix polymers to which other bacteria may bind, rather than to the 
pellicle, resulting in a complex biofilm of spatially arranged species eventually forming 
dental plaque (19,57,65). The polysaccharide layer serves as a nutrient to aid in the 
growth of bacteria, and is important for protection of the bacterial cells from the osmotic 
effects of sucrose, the inhibitory effect of toxic metabolic end products, antimicrobials, 
and the host’s immune mechanisms (19,57,69,70).  
Pathogenesis  
 One factor contributing to mechanically ventilated patients acquiring VAP is the 
inability of their compromised host defenses to protect against endogenous and 
exogenous infections (4,32). When these patients are overwhelmed with a high inoculum 
of organisms, the impaired defense system is unable to clear or inactivate the organisms 
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which can then colonize and lead to the development of pneumonia (32). The normal 
human respiratory tract possesses a variety of defense mechanisms that protect the lung 
from infection (32). Anatomic barriers include the glottis and larynx, cough reflexes; 
tracheobronchial secretions, mucociliary lining, cell-mediated and humoral immunity; 
and a dual phagocytic system that involves both alveolar macrophages and neutrophils 
(32). Mechanical ventilation contributes to a break in the defense system with increased 
frequency of colonization among patients with respiratory disease, sputum production, or 
endotracheal intubation; this suggests that conditions that impair lung clearance may also 
promote colonization (59). Major host determinants interfering with the mucosa-
associated defense system includes disease-induced changes of the upper respiratory tract 
resulting from severity of an underlying illness, or advanced age which may also increase 
oropharyngeal colonization by GNB (46,58,71,72).  
 Respiratory assistance devices bypass essential host defenses and allow pathogens 
direct access to the lower respiratory tract and hinder the ability of these defense systems 
to effectively clear respiratory pathogens (1). The response of the body’s defense system 
results in modifications of the respiratory epithelium that favor colonization by 
respiratory pathogens (19). With mechanical ventilation patients will have an automatic 
breakdown of host defenses by bypassing the host natural defense system with an 
artificial airway that compromises the natural barrier between the oropharynx and trachea 
(32). Starting as early as 12 hours after intubation, biofilm formation occurs with many 
patients undergoing mechanical ventilation (31,67,73). Bacterial biofilms may cause 
inflammation around the vocal cords and upper airway from leakage of oropharyngeal 
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secretions from above and below the endotracheal tube cuff  (19,74,75). Biofilm particles 
on the inner surface of the endotracheal tube can detach and inoculate the lower 
respiratory tract from ventilatory-induced breaths, endotracheal suctioning, and 
bronchoscopy (19,24,31,76).   
 Endotracheal tubes, contaminated respiratory equipment, position of the patient, 
parenteral nutrition support, and insufficient head elevation in bed provide a route for 
colonizing pathogens to translocate from the oral cavity to the oropharynx and colonize 
the upper airway during mechanical ventilation (19,31,77). Respiratory equipment 
associated with mechanical ventilators, such as humidifying cascades and contaminated 
reservoir nebulizers, serve as reservoirs for condensate and deliver the contaminated 
condensate to the patient (74). Usually the extrinsic contamination of the patient’s 
ventilator circuit results from inoculation of large amounts of fluid with high bacterial 
concentrations produced from warm humidified air (74). Aspiration of contaminated 
secretions by the patient is facilitated by manipulation of ventilator tubing, patient 
transport, delivery of aerosolized medication, or placing the patient in a supine position 
(33,78,79). Ventilator tubing has been found as the primary factor for colonized bacteria; 
the highest levels of colonization (>1,000 CFU) have been found to occur at parts nearest 
to the patient (74,80). It has thus been hypothesized that the enteric microorganisms that 
colonize the stomach migrate to the oropharynx, and eventually reach the lungs of 
mechanically-ventilated patients via aspiration (60). When factoring other devices such 
as a nasogastric or orogastric tube, patients have a greater chance of developing 
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nosocomial pneumonia from aspirating gastric contents or stagnant oropharyngeal 
secretions into the lower airways while in the supine position (33,79,81).  
 Even with an artificial airway, a patient is also still susceptible to VAP with micro-
aspiration (19,82). Mechanical ventilation causes changes in the cuff pressures, 
deforming it and allowing the secretions to be transported around it by capillary action 
thereby increasing the risk for microaspiration (19,83). Local trauma and inflammation 
caused by an endotracheal tube and possible leakage of contaminated secretions around 
the cuff and into the upper trachea increase lower airway colonization and the risk of 
tracheobronchitis and VAP (74,75). Reintubation magnifies the risk of aspiration of 
colonized oropharyngeal and gastric secretions into the lower airways (32). 
 Colonization of the upper respiratory tract (i.e., the oropharynx and trachea) by 
potentially pathogenic microorganisms is common in critically ill, mechanically-
ventilated patients (60). Patients with chronic illnesses have more difficulty maintaining 
optimal oral hygiene, often because of a reduction in the natural cleansing of the mouth 
and/or reduced saliva from certain medications (19,46,58). If oral hygiene is neglected 
the accumulation of plaque can lead to gingivitis and a shift to aerobic Gram-negative 
bacilli (57). An ICU patient with an increased length of stay (more than five days) will 
more than likely see a dramatic decrease in oral hygiene and an increase in colonizing 
GNB and S. aureus in the upper airway (24,32,84). Oral flora can be affected by 
macroenvironmental changes associated with routine hospital care and respiratory 
equipment that exposes the patient to Gram-negative bacilli (43,74,85). Therefore, 
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tracheal colonization and other multifactorial risk factors are very important in the 
emergence of VAP (77). 
Diagnosis  
 Evidence from Fàbregas et al., indicates that clinical diagnosis of VAP is associated 
with about 30 to 35% false-negative and 20 to 25% false-positive results (86). A major 
diagnostic dilemma for VAP is that no one specific criterion is available to give a 
definitive diagnosis. Yet, an accurate and specific diagnosis is critical for pneumonia 
treatment and prevention. With patients in the ICU comprising up to 10% of total cases of 
pneumonia, rapid identification of infection is important for appropriate antimicrobial 
treatment to prevent emergence of MDR pathogens (32,53). With the misdiagnosis of 
VAP, inappropriate clinical treatment often leads to a substantial source for morbidity 
and mortality (24). The inability to identify patients with VAP, treating those with VAP, 
treating those with VAP inappropriately may also potentially put them at risk for 
developing superinfections (24,31). For example, if a patient is treated empirically, but 
does not have an infection, the organisms that subsequently infect the patient may be 
either multidrug-resistant Gram-negative bacteria or MRSA, and the mortality risk will 
be increased (87).   
 Diagnosis relies heavily on clinical signs. However, these clinical signs can inflate 
incidence rates, which can impact the reportable impact of VAP mortality. In fact, 
clinical signs such as pulmonary infiltrates or tracheobronchial colonization do not 
necessarily mean that the patient has VAP (24,31,32,88). Radiographic infiltrates, other 
sources of fever, results of Gram staining and culture of tracheal aspirates can lead to 
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misdiagnosis and poor choices for the antibiotics (24,32). The differential diagnosis of 
VAP may include chemical pneumonitis, cardiogenic and noncardiogenic pulmonary 
edema, pulmonary thromboembolis, or persistent atelectasis, aspiration, pulmonary 
embolism, or acute respiratory distress syndrome (31,32,53,75).   
 The traditional criteria for diagnosing VAP are generally non-specific systemic 
symptoms that are typically found in all forms of pneumonia. The traditional criteria for 
clinical signs include new or worsening infiltrates seen on the chest radiograph, and 
bacteriologic evidence of pulmonary parenchymal infection (18,19,32,88). Some 
traditional nonspecific clinical symptoms include fever, leukocytosis, increase in 
respiratory secretions, purulent sputum, and pulmonary consolidation on physical 
examination, along with a new or changing radiographic infiltrate (19,24,26,32,89,90). 
Non-specific clinical findings may have alternative causes, including antibiotic-
associated diarrhea, sinusitis, urinary tract infection, pancreatitis, and fever (24,80). 
Clinical signs that are more specific for diagnosing VAP include fever higher than 
100.9°F, leukocytosis (25% increase and value greater than 10,000 mm3), leukopenia 
(25% decrease and value less than 5,000 mm3), or purulent tracheal secretions (58,63).  
 The evaluation of these signs, using the Clinical Pulmonary Infection Score (CPIS) 
recommended by the CDC, provides a numerical value for diagnosing VAP. The CPIS 
score usually sets precedence in identifying the need for more invasive diagnostic tests, 
such as obtaining tracheal aspirates, and in helping identify low-risk patients in need of 
short-course antibiotic therapy (24,83). The most important component and backbone for 
clinical diagnosis in evaluating hospitalized patients with suspected pneumonia, is a chest 
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x-ray (31,32,89). Chest x-rays provide detection of progressive infiltrates such as a 
bronchopneumonia pattern, common in nosocomial pneumonias, whereas a lobar pattern 
is more common in bacterial CAP (24,31,89). If a new or persistent infiltrate is seen on a 
chest x-ray, the next step is to isolate an organism from sputum or pleural fluid, or a 
positive culture from a bronchoalveolar lavage, must be present (63). The drawbacks of 
chest x-rays are that they are not reproducible and lack specificity for differentiating 
among pulmonary processes that radiographically mimic pneumonia (24,31,32,53,75).  
As a result of the inaccuracies associated with the clinical approaches to VAP, many 
investigators have developed specialized diagnostic methods. Some methods include 
quantitative cultures of endotracheal aspirates obtained using bronchoscopic techniques 
such as bronchoalveolar lavage (BAL) and/or a protected specimen brush (PSB) (32).  
 In diagnosing pneumonia in intensive care unit patients, current practice is to rely 
heavily on analysis of sputum Gram stain (53). According to Salata et al., analysis of 
sputum using Gram stain provides a semi-quantitative estimate of bacteria (53). The 
absence of bacteria in Gram-stained endotracheal aspirates makes pneumonia an unlikely 
cause of fever or pulmonary infiltrates (24). Carefully performed Gram staining of 
purulent sputum specimens with few squamous cells present have been helpful in 
establishing a rapid diagnosis of pneumonia caused by pneumococci, staphylococci, and 
Gram-negative bacilli (53).  
 A diagnostic challenge for the microbiology laboratory is the need to differentiate 
between organisms responsible for infection and colonizing flora (91). Invasive 
techniques are the best method for alleviating this problem by obtaining a specimen with 
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the least amount of oropharyngeal contaminants (31,32). It is also the best method for 
rapid diagnosis for pneumonia caused by pneumococci, staphylococci, and invasive 
Gram-negative bacilli (49). It is believed that the bronchoscopic quantitative cultures are 
most effective, decreasing mortality among VAP patients by preventing inappropriate 
selection of antibiotics, and identifying other potential sources of infection (24). Invasive 
testing which leads to more accurate diagnosis and treatment has the advantage of 
reducing the risk of antimicrobial resistance, producing fewer side effects from 
unnecessary antibiotics, and a decrease in cost (87). Culture and sensitivity tests are best 
done as early as possible from all patients without contraindications (92). 
 Quantitative endotracheal aspirate cultures may be an adequate tool for diagnosing 
pneumonia when no fiberoptic techniques are available (32). Quantitative cultures are 
critical and complement clinical data by identifying patients with true VAP, facilitating 
appropriate treatment, and discriminating between colonization and true infection (24). It 
must be kept in mind that this quantitative technique has several potential pitfalls such as 
using the cutoff value of 106 CFU/ml (32). This cutoff value may contain contaminants 
since endotracheal aspirates obtained through bronchoscopic secretion samples have 
higher levels of organisms (32,92). 
 The role of quantitative invasive diagnostic techniques to evaluate patients with 
clinical evidence of nosocomial pneumonia remains controversial (88). The controversy 
centers around whether invasive techniques should be used on a routine basis or rather on 
a targeted basis to diagnose pneumonia (88). Bronchoscopic techniques, when performed 
before introduction of new antibiotics, enable physicians to identify most patients who 
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need immediate treatment and help to select optimal therapy in a manner that is safe and 
well tolerated (32). As soon as a lower threshold is used, specificity declines sharply and 
overtreatment becomes a problem (32). Contaminants found in bronchoscopic secretion 
samples are usually present at less than 104 CFU/ml (93). Higher levels of infecting 
organisms causing nosocomial pneumonia are usually present in concentrations of 105 to 
106 CFU/ml (51,93). With such narrow values of the aforementioned concentrations, the 
quantitative technique is designed to distinguish between contaminants and infecting 
organisms (51,93). 
 The results of microbiological tests of sputum specimens obtained by either invasive 
or noninvasive methods are not sufficient to determine if pneumonia has resolved or the 
success of antibacterial treatment and the host defense system but can provide a 
quantitative and qualitative assessment of burden present in the lung tissue. However, the 
culture and sensitivity results can help in choosing an antibiotic (24,32). Microbiologic 
test results from sputum specimens have a high sensitivity for nonspecific bacterial 
pathogens. Due to the high sensitivity of microbiologic tests to nonspecific bacterial 
pathogens, the test should not be the sole basis for diagnosing VAP (31). 
 The two techniques that are considered superior but still controversial are protected 
specimen brush (PSB) and bronchoalveolar lavage (BAL) (32). Diagnoses achieved with 
invasive tests have led to a change in antibiotic in up to 50% of cases (87). For those with 
clinical signs of pneumonia, it has been noted that test results from tracheal aspirates 
correlate well with those from PSB (87). Results from studies have indicated that the PSB 
technique offers a sensitive and specific approach to identifying the microorganisms 
	  	  	  21   
involved in pneumonia in critically ill patients, and to differentiate between colonization 
of the upper respiratory tract and distal lung infection. Kirtland et al. (1997) has shown 
that a PSB culture with ≥103 CFU was 100% sensitive in association with histologic 
pneumonia in patients with or without antibiotics with a negative predictive value of 
100% (94). In patients receiving antibiotics, the specificity was 42% and positive 
predictive value was 22% compared with 87% and 80%, respectively, in patients not 
receiving antibiotics (94). Bronchoalveolar lavage technique is safe, efficient, and 
practical by providing immediate examination of the cells and secretions obtained from 
the large area of lung (32). 
 The major dilemma with all bronchoscopic techniques is selecting the proper 
sampling area in the tracheobronchial tree. Sampling the distal airways of the respiratory 
system produces specimens that are more reliable for diagnosing pneumonia (24,32). As 
discussed previously, BAL is a safe and effective method of obtaining specimens. 
Nonetheless, BAL may also affect the validity of results depending on the sampling area 
from which the diluted material is retrieved. Diluted material from the bronchial area 
rather than from the alveolar level will often give rise to false-negative results (32). 
Contamination can occur despite using a fiberoptic bronchoscope (FOB) in combination 
with either BAL or PSB. Any type of bronchoscope passing through the endotracheal 
tube and proximal airways plus aspiration of distal secretions may become contaminated 
with organisms from the normal flora (32). Besides contamination of the specimens, a 
patient is at risk for health complications when performing this procedure. The risk 
appears slight, even for critically ill patients requiring MV, although the associated 
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occurrence of cardiac arrhythmias, hypoxemia, or bronchospasm is not unusual 
(32,95,96). Patients in the ICU are at risk of relative hypoxemia during fiberoptic 
bronchoscopy even when high-level oxygen is provided to the ventilator and gas leaks 
around the endoscope (95). BAL could be performed without significant risk to most of 
the patients in the ICU (96).  
 Multiple studies have shown that both bronchoscopic and nonbronchoscopic BAL 
are significantly more sensitive and specific than nonquantitative endotracheal aspirate 
cultures in microbiologic diagnosis of pneumonia in mechanically-ventilated patients 
(88). Nonbronchoscopic techniques have also been developed for the evaluation of VAP, 
but they have the same limitations as those noted above for the bronchoscopic methods 
(97). However, nonbronchoscopic approaches have been advocated as potentially better 
alternatives because of their minimal invasiveness, wide availability, and relative 
inexpensiveness compared with fiberoptic bronchoscopy (97). 
Treatment  
 For an overall successful treatment of VAP, optimal antibiotic treatment must be 
provided in a strategic manner (24,98). A different strategy for management of VAP 
involves some form of clinical and microbiological assessment (98). For any given 
patient, clinical management of VAP may include knowledge about local patterns of 
antimicrobial resistance, particularly in the ICU setting, administration of antibiotics, and 
the patterns of resistance of the most likely pathogen (24,88). The upper respiratory tract 
of most ICU patients with pneumonia remains colonized with multiple potential 
	  	  	  23   
pathogens (32). One factor in managing VAP involves using Gram stains of endotracheal 
aspirates as a guide for antimicrobial therapy along with diagnosing pneumonia (98). 
 The mainstay of VAP treatment is systemic antibiotic therapy in addition to 
maintenance of adequate perfusion and hydration, prevention of atelectasis, provision of 
aggressive pulmonary toilet, and weaning from mechanical ventilation as quickly as 
possible (88). Prevalence of antimicrobial resistance among VAP pathogens is steadily 
increasing especially against broad-spectrum antimicrobial drugs (88). There is some 
controversy regarding the role of antimicrobial therapy in preventing, treating, or putting 
patients at risk for VAP (99). The absence of antimicrobial therapy as a risk factor for 
VAP has not been identified but it has been found that prior antibiotic use was a risk 
factor for VAP (100). Prophylactic short-course treatment has been shown to provide a 
major benefit in decreasing the incidence of early-onset VAP, which is caused by the less 
pathogenic microorganisms (24). 
 Yet, insufficient treatment is common in VAP, ranging from 20% to 70%, and is 
associated with increased resource utilization, including increased ventilator days and 
increased length of stay (88). Inadequate initial antimicrobial treatment may also affect 
the emergence of infections resulting from antibiotic-resistant bacteria, and subsequent 
increased mortality rates in patients by facilitating colonization and superinfection with 
multiresistant microorganisms (24,32,88,98). MRSA is an important cause of VAP 
associated with high rates of inadequate initial empiric antimicrobial therapy and poor 
clinical outcomes (98). Treating VAP becomes complicated with an inadequate initial 
antibiotic regimen. This inadequate initial treatment may also result in an increased 
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morbidity and mortality (98). In general, the likelihood of MDR pathogens such as 
Pseudomanas aeruginosa, Acinetobacter species, Stenotrophomonas maltophilia, and 
MRSA causing VAP depends on the duration of hospitalization prior to the onset of VAP 
and other risk factors for MDR pathogens (98). Late-onset pneumonia that occurred 
without antibiotics during the 15 days preceding the onset of infection largely were 
caused by Streptococci, MSSA, or Enterobacteriaceae (29). Recently received antibiotics 
for late-onset pneumonias were the result of MDR pathogens such as P. aeruginosa, A. 
baumannii, or MRSA in more than 40% of cases (29). 
 Selection of antimicrobial therapy for VAP is complex and increases the cost of 
treatment due to antimicrobial-resistant pathogens (98). When selecting a highly 
recommended broad-spectrum empirical treatment for VAP, one should be aware of 
underlying diseases and specific risk factors that may predispose patients to infection 
with specific organisms, especially MDR pathogens (29). Other factors include the 
epidemiologic characteristics of the patient, clinical examination of pulmonary 
secretions, and how the drug will absorb, distribute, metabolize, and exit the body 
(29,98). Primarily a broad-spectrum antibiotic regimen is selected to cover all potential 
pathogens both Gram-negative and Gram-positive including MDR pathogens (88,98). 
Two of the most common organisms isolated in HAP and VAP are Pseudomonas and S 
aureus (88). Antibiotics that can be considered in VAP treatment include the 
semisynthetic penicillins, fluoroquinolones, fourth-generation cephalosporin, and 
carbapenems (88). Infection due to antimicrobial-resistant pathogens necessitates broad-
spectrum initial empiric antimicrobial therapy, usually with a combination of drugs (98). 
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In patients with severe infection due to P. aeruginosa or other MDR bacteria, such as 
Klebsiella spp. or Acinetobacter spp., combination therapy of antipseudomonal beta-
lactam with an aminoglycoside or ciprofloxacin is likely to obtain a much better outcome 
than monotherapy (24,29). The standard recommendation requires two drugs directed at 
P. aeruginosa and one at MRSA (24). Still it is suggested to reduce the antibiotic 
regimen to a single agent in more than half of the cases and to a two-drug combination in 
more than one-quarter for those patients at risk for experiencing MDR pathogens (24).  
 Once sputum or BAL culture results are obtained and a confirmed etiologic 
diagnosis is reached, a broad-spectrum empiric therapy can be modified and/or tapered 
down to address the known pathogen specifically while avoiding prolonged use of broad 
spectrum drugs (24,29,88). This strategy is known as de-escalation. De-escalation 
modifies antimicrobial treatment from aggressive broad-spectrum initial empiric 
antimicrobial therapy to a more narrow spectrum, or discontinuation of antimicrobial 
drugs (98). Drugs with a narrow spectrum that target the known pathogens are substituted 
for drugs with an unnecessarily broad spectrum in order to minimize excessive 
antimicrobial exposure (98). Even if a de-escalating approach to antibiotic therapy does 
not benefit the individual patient, the modification of therapy can reduce the selection for 
resistant strains of bacteria to develop in the ICU (29). Prolonged courses of antibiotic 
treatment demonstrated a consistent increased risk for VAP due to the more lethal MDR 
pathogens (24). It is rare for patients to require a complete antibiotic regimen of three 
drugs and other trials subgroup analyses have not found an increase in benefit with such a 
regimen (24). Furthermore randomized controlled trials have demonstrated a concrete 
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benefit with just a two-combination therapy such as beta-lactam and aminoglycoside 
(24). 
 The recommended duration of antibiotics depends on the severity of disease, the 
time to clinical response, and the microorganism(s) responsible (29). The recommended 
duration of therapy for hospital-acquired pneumonia, including VAP, has traditionally 
been long: a minimum of 7–10 days for patients at risk for Haemophilus or 
Staphylococcus infections, and 14–21 days for more typical cases (98). The optimal 
duration of therapy remains unknown, but in the last several years a number of clinical 
studies have lent support to using shorter courses of treatment (98). The general strategy 
of limiting the duration of therapy has been fully endorsed by the new American Thoracic 
Society/Infectious Diseases Society of America guidelines for the management of VAP 
(98). Treatment of at least 14 to 21 days is prescribed for patients with multilobular 
involvement, malnutrition, cavitation, Gram-negative necrotizing pneumonia, and 
infections P. aeruginosa or Acinetobacter spp., which correspond to the majority of 
pulmonary infections occurring in patients requiring mechanical ventilation (29). 
 Effective antibiotic treatment depends on the adequate delivery of the antibacterial 
agent, i.e. optimal doses of the drug that can be safely achieved and maintained at the site 
of the infection, a route of administration with minimal side effects, the antimicrobial 
efficacy of the drug against each infectious agent, local patterns of antimicrobial 
resistance, and the patient’s prior antibiotic exposure (24,29,98,99). Clinical 
improvement, if it occurs, is usually evident within 48–72 h of initiation of antimicrobial 
treatment (24). Findings on chest radiography often worsen initially during treatment; 
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they are less helpful than clinical criteria as an indicator of clinical response in severe 
pneumonia (24). Clinical response to treatment is usually tracked by repeating 
quantitative cultures to show the microbiologic response (24). 
 Treatment failure, due to deficiencies in the antibiotic treatment, is common in VAP 
patients before obtaining a definitive diagnosis for the pathogens responsible for the 
pneumonia (29). Signs such as an elevated or rising clinical pulmonary infection score 
(CPIS) value by day three of ventilation, especially with declining or poor oxygenation, 
is a strong indicator of treatment failure (24). CPIS is a score used in diagnosing VAP. 
The score is calculated on the basis of points assigned for various signs and symptoms of 
pneumonia. A CPIS >6 usually suggests VAP (7,27,51). Treatment failure due to an 
inadequate differential diagnosis may result from a new super infection causing the 
pneumonia, the presence of extrapulmonary infection and drug toxicity (24). 
Prevention  
 Understanding the development of VAP and learning to recognize patients at risk 
permit an opportunity to implement simple but effective preventive measures (101). 
Despite the introduction and use of broad-spectrum antimicrobial agents, management of 
ventilator-dependent patients, and routine use of disinfecting respiratory equipment, VAP 
remains a cause of mortality, morbidity, and increases in healthcare costs (33). 
Decreasing the exposure to potential pathogens involves a collaborative effort among all 
healthcare professionals. When developing a strategic prevention plan for VAP, one must 
take into consideration a general framework of preventing VAP by decreasing the 
exposure of oropharyngeal secretions drifting toward to the lower respiratory tree, 
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modifying the virulence and/or quantities of the microorganisms present in the 
oropharynx, and improving host defenses (31,33,101).  
 The simplest way to prevent VAP is to avoid endotracheal intubation and use a less 
noninvasive method of ventilation. If an endotracheal tube is used, it is best to use a 
modified orotracheal tube that allows removal of secretions above the endotracheal tube 
cuff, and minimize the time a patient is required to have an endotracheal tube in place 
(24). Once a patient is intubated, patient care should focus on aspiration of bacteria in the 
patient airway. Protection of the airway with invasive procedures such as tracheal 
intubation sometimes cannot be avoided but other available preventive measures still 
exist as not to further contribute to the risk of VAP (31). Measures taken to prevent 
aspiration include maintaining an appropriate level of no less than 20 cm of H20 in the 
endotracheal tube cuff, elevating the head of the bed at least 30o to 45o, and adjusting the 
patient’s position every two hours (31,101,102). Potential weaning, extubation from 
mechanical ventilation, and the use of heavy sedation are also taken into consideration to 
decrease the risk of VAP (31). In 1981, the CDC published guidelines with a traditional 
approach through infection control to prevent and control the spread of nosocomial 
pneumonia (18,19). This approach limited person-to-person spread of infection by 
wearing protective equipment, hand washing, and improving care of invasive devices 
(101,103). Often these traditional measures fail because they have little effect on the 
patient’s endogenous flora, which is an important source of infection in intensive care 
units (103). 
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 Tracheal colonization precedes VAP in most patients but only a minority develops 
VAP (77). Oral flora can be affected by macroenvironmental changes associated with 
routine hospital care and respiratory equipment that expose the patient to Gram-negative 
bacilli (43,74,85). Researchers agree that prevention methods should focus more on 
decreasing the ability of VAP-associated pathogens to colonize the oral cavity preceding 
infection of the lower respiratory system (104). The CDC addressed the need to impede 
pathogens from translocating to other parts of the body. In 2003, the CDC guidelines 
provided ways for decreasing the number of opportunistic pathogens in the normal flora, 
and improving a patient’s immune system in response to acquired pathogens 
(18,19,33,105). Adequate oral hygiene has shown to decrease elevated enzymes such as 
neuraminidases and proteases, which can modify bacterial colonization and attachment 
(61). Theses enzymes are derived from inflammatory cells associated with gingival 
inflammation and bacterial plaque accumulations (61). These enzymes generate hidden 
receptors for bacterial adhesions that promote colonization of certain Gram-negative 
bacteria (61). With oral hygiene neglected, the accumulation of plaque can lead to 
gingivitis and a shift to aerobic Gram-negative bacilli including those known to cause 
pneumonia (57). 
 The question that arises for many clinicians is how does one provide adequate oral 
healthcare with these devices overcrowding the mouth. An adult size toothbrush is not 
able to fit thus leaving healthcare providers discouraged and frustrated. Yet, if normal 
adult size oral healthcare products are used, there may be a risk of dislodging the 
protective airway equipment (65). Challenges arise when attempting to provide adequate 
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oral care to a ventilated patient. With devices such as endotracheal, oral gastric tubes, and 
occasionally a temperature probe crowding the mouth, healthcare providers become 
frustrated trying not to dislodge these important medical devices, compromising the 
patient’s airway (31,83,106). Mechanical obstacles, perceptions of importance, patient 
discomfort by the nurse and family members, patient perception and ineffective 
communication are key barriers to achieving optimal oral hygiene (65). 
 Prevention measures for nosocomial infections can enhance a patient’s quality of life 
and our nation’s economy. Oral care practices vary among healthcare institutions with 
university and private nonprofit hospitals providing the least amount of care (82). The 
most effective and correct method of providing oral hygiene to ventilator patients is still 
unclear and there is a substantiated need to standardize oral care (63,65). Three protocols 
developed specifically for mechanically-ventilated patients encompass an oral 
assessment, a pediatric toothbrush, toothpaste, mouth rinses, and petroleum jelly for the 
lips with a frequency ranging from every 2 to 12 hours, and routine suctioning of 
secretions above the endotracheal tube (82,101). There are numerous methods and mouth 
rinses that can be used to improve oral hygiene in ventilator patients, but the most 
effective method with respect to concentration, frequency, and application is still unclear 
(29). The medical community continues to search for an effective standard of oral care.  
Some researchers have identified a unique element of oral care such as chlorhexidine 
gluconate (CHX) oral rinse. This antimicrobial reducing agent has been recognized as the 
“gold standard” for oral care (7,32,107,108). 
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 Chlorhexidine gluconate is a cationic antiseptic compound solution that binds to the 
negatively charged hydroxyapatite of tooth enamel, the extracellular polysaccharide of 
plaque, and mucous membranes within the oral cavity inhibiting bacterial colonization 
and pellicle formation (57,65,81,109). Chlorhexidine reduces microbial adherence to the 
tooth and mucosal surfaces by attaching to the bacterial cell wall structures and altering 
the cell osmotic equilibrium. As a result, potassium and phosphorous leak and damage 
the cell contents (65). Therapeutic benefits of chlorhexidine include a reduction in 
bacterial plaque, gingivitis, and dental caries (57). 
 The use of preventive oral washes with chlorhexidine therefore seems reasonable in 
selected high-risk patients, given the easy administration and the reasonable costs (81). 
The use of oral antiseptic and antimicrobial agents to prevent nosocomial pneumonia has 
been widely studied, and based on what has been reported, changing the oral environment 
can reduce nosocomial pneumonia (19). When antimicrobial mouthrinses are used daily 
along with brushing and flossing, they are most effective in reducing plaque and 
gingivitis (110). Yet there are conflicting studies on whether antimicrobial solutions, used 
alone or in combination with chlorhexidine, may significantly improve the oral health of 
mechanically-ventilated patients (82,111). 
 This systematic review will address the importance of oral health and the increased 
risk of respiratory infections from colonization with harmful pathogens within the oral 
cavity.  Furthermore, this review will investigate the efficacy of chlorhexidine, excluding 
other prevention measures, in reducing VAP. Risk factors including bacterial 
mechanisms of oropharyngeal colonization that contribute to acquiring ventilator-
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associated pneumonia will be examined and prevention measures needed to prevent VAP 
will be detailed. The methods and results presented were determined from conducting a 
comprehensive literature search. For organizational purposes, the databases and terms 
used for the searches are documented in a table format. Results from each database 
include the number of articles retrieved, duplicate citations, and studies of interest for 
review. Articles from the literature search were carefully reviewed for relevance and 
evaluated as background information for clinical trials relating to chlorhexidine oral 
rinse. Clinical trials relating to the hypothesis of this thesis were evaluated using the 
Consolidated Standards of Reporting Trials (CONSORT) checklist for validity. All 
studies meeting the CONSORT criteria were separated into specific categories for a 
critical review and analysis. Based on the designated categories in the results section, the 
results from analyzing all clinical trials studies reflect strengths, weakness, and 
limitations in the discussion. This summary of data provides the best method to 
administer CHX oral rinse for all VAP protocols and evaluates the effectiveness of CHX 
oral rinse in preventing VAP, excluding other prevention measures. A brief synopsis of 
all content presented in the systematic review provides a concise list of prevention 
measures to reduce the incidence of VAP rates and recommendations for further research.   
 
	  	  	  33   
PUBLISHED STUDIES 
 
 This systematic review identifies published randomized clinical trials relating to the 
effectiveness of CHX gluconate (oral rinse) in preventing VAP. These intervention 
studies assess the efficacy of CHX gluconate (oral rinse) and provide recommendations 
for more specific measures for future clinical trials. To assist with analyzing CHX 
gluconate (oral rinse), a literature search was conducted to identify published randomized 
clinical trials studies relating to the efficacy of CHX gluconate oral rinse in preventing 
VAP. The electronic databases provided by Boston University Medical Center (BUMC) 
Alumni Medical Library’s educational resources were accessed to identify relevant 
evidence evaluating chlorhexidine pertaining to VAP reduction. Nine bibliographic 
databases, from 1965-2012 were used to conduct the literature inquiry. The databases 
searched included PubMed, Ovid, Gale Group, Medline, JSTOR, SAGE, Springerlink, 
Wiley, Biomedcentral, WorldCat, Science Direct, and Cochrane Library-Wiley. Online 
electronic databases accessed from Boston University Medical Campus (BUMC) Alumni 
Medical Library’s bibliographic and knowledge databases included British Medical 
Journal, American Journal of Critical Care, American Journal of Respiratory Care, 
American Chest, Academic Onefile, BioMedCentral, Elsevier ScienceDirect, New 
England Journal of Medicine, Journal of American Medical Association (JAMA), and 
Annals of Internal Medicine. Medical Subject Headings (MeSH) keywords utilized for 
PubMED included ventilator-associated pneumonia, oral rinse, chlorhexidine, 
mouthwash, prevention, nosocomial pneumonia, oral rinse, chlorhexidine gluconate, and 
VAP. A combination of MESH terms included chlorhexidine, ventilator, pneumonia, 
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VAP, oral care, mouth care. The aforementioned MESH combination keywords were also 
used for bibliographic and knowledge databases. Language of the study was not excluded 
from the original literature search, but foreign language randomized trials were not 
included in the systematic review. The bibliographic software RefWorks was used to 
record and manage references and retrieve journals. All results from the literature search 
were imported to the RefWorks software and organized into folders corresponding to the 
database accessed to produce the entry title. As shown in Figure 1, the initial search titles 
and abstracts were reviewed and examined thoroughly for meeting the inclusion criteria. 
Studies included in this systematic review included randomized controlled trial or clinical 
trial conducted on adult humans who were mechanically ventilated or treated with 
chlorhexidine gluconate oral rinse. The study participants exposed to CHX oral rinse 
used as an intervention, must also have had a clearly defined outcome such as decreasing 
potential respiratory pathogens located in the oral cavity and/or a declining VAP rate. 
Exclusion criteria were in situ, in vitro or of split-mouth design, if the chlorhexidine 
gluconate intervention could not be ascertained, or if outcomes were not clear. Entries 
also excluded for further evaluation included duplicate citations, those focusing on 
mechanically-ventilated patient groups under the age of 18, studies not available in full-
text or the English language, product reports or abstracts, dissertations, and non-clinical 
trials focused on exposure other than the supplemental chlorhexidine use. The excluded 
studies were organized in the RefWorks software according to whether or not they met or 
the inclusion criteria and the reason(s) why the citation was not included in the systematic 
review.  
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Figure 1:  Flow chart of systematic review process  
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The full text articles were retrieved for all titles and abstracts indicating that a citation 
was relevant for review, and then each full text article was reviewed. For studies that 
appeared to meet the inclusion criteria but a definite decision could not be made based on 
title and/or abstract, the full text article was retrieved for detailed assessment. Rejected 
citations were those that were evidently not related to the research question. A manual 
search in the library was also conducted on titles that seemed vague and did not have an 
abstract to determine if the article should be included or excluded. A manual search was 
executed for applicable references cited in the publications included in this literature 
review. The remaining articles included clinical trials, foreign language and English 
language abstracts.   
 Studies were read and data extracted for each of the included studies in the final 
review document. For the full text articles included, the author’s definition of VAP for 
each trial was accepted and then further evaluated based on the CDC guidelines. Studies 
were analyzed for quality and consistency of results from randomized control trials. The 
quality and strength of each randomized clinical trial was evaluated based on the 
requirements of the Agency for Healthcare Research and Quality (AHRQ). The quality 
and evaluation of studies that were included in this review were rated based on the 
domains and the associated elements shown in Table 1. The elements provided for each 
domain are in bold and were given a maximum score of 1.0; nonessential elements were 
given a maximum score of 0.25. Each article was scored from 0 to 13. For each study, 
data were extracted to develop Evidence Table 2 identifying population description, risk 
	  	  	  37   
assessment, statistical findings, and outcomes related to VAP prevention or decrease in 
pathogens related to the VAP intervention.  
Table 1:  Domain and Elements 
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Table 1 (Cont'd): Domain and Elements 
	  
 
Elements appearing in bold are considered Essential elements 
Bolded items= 1pt, non bolded= 0.25 points; maximum total = 13pts 
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RESULTS 
           The total number of articles retrieved for the systematic review was 991. 
The number of duplicate citations was 95 which included both English and foreign 
articles. Out of the number retrieved, 946 entries were in the English language; 45 were 
foreign language entries with 31 retained for further review (See Figure 1). Pubmed 
produced the most entries when using a combination of key words totaling 538 entries; in 
which 127 of which met the qualifications for further review. From the entries accessed 
using OvidMedline and ScienceDirect databases, similar results were obtained. Out of the 
94 articles produced by OvidMedline, 55 articles met the requirements for full text 
retrieval and review. Science Direct produced 104 articles for full text review. The Gale 
Group database produced 67 entries of which 57 were retrieved. Wiley produced 24 
entries, 16 from Springerlink, and 11 from Sage. Many articles were not included due to 
being published in another language without available translation. Of the 39 foreign 
language titles, 10 warranted further evaluation. All 10 titles included English language 
abstracts but none were appropriate for inclusion in the final evaluation of articles. Other 
entries were from BU libraries and physical holdings. From the original literature search, 
120 references were manually searched in the library. After reviewing or scanning the 
references from the initial search, 462 entries were accessed. From screening the 
abstracts, 330 journal entries were excluded. If the abstract was not available then the full 
text article was retrieved. Out of the 462 articles, 419 full text articles were assessed as 
meeting all the inclusion criteria. The remaining 122 full text articles that were excluded 
resulted in 10 studies meeting the inclusion criteria for this review. Of the ten studies 
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included in the final systematic review of chlorhexidine gluconate, information was 
gathered from each study, organized for further review and analysis. 
 A synopsis of the ten studies included in the final systematic review of 
chlorhexidine gluconate is presented in Table 2. These ten studies had populations ≥ 18 
years of age, admitted to the intensive care unit receiving mechanical ventilation. The 
patients were at risk for VAP either from trauma, undergoing elective cardiothoracic 
surgery, or some other form of surgery. Results from this review were categorized by the 
various strengths of chlorhexidine used: 0.12% CHX oral solution [7 studies (6,47,112-
116)], 2% CHX solution (117) and 0.2% CHX oral rinse [2 studies (118,119)]. 
 Table 3 presents the overall quality score for each trial rated good in bold. The 
table also assesses the internal and external validity of the ten studies. The majority of the 
studies were of good quality in all domains. Internal validity includes the domain 
elements of randomization, blinding, clearly detailed interventions, and appropriate 
statistical analysis, all of which are valuable in strengthening the validity of the study. 
Four of the ten studies had quality scores rated as good, with representation in 0.12% and 
0.2% categories of chlorhexidine gluconate but not for the category of 2% chlorhexidine 
gluconate oral rinse. When analyzing the ten studies with respect to at least three of the 
domains comprising internal validity, they were considered overall good quality studies. 
The independent study domains were evaluated as good in the following order: 
interventions, statistical analysis, blinding, and randomization. Three of the ten studies 
were of good quality (randomization, blinding, and statistical analysis) with all different 
strengths of chlorhexidine represented. For most of the studies, a quality rating of good 
	  	  	  46   
was noted in at least one domain. When assessing the internal validity of all of the quality 
domains, the well-detailed interventions had the highest value for strengthening the 
overall quality of each of the ten studies.   
 External validity or generalizability also predicts how applicable these findings 
may be to a larger community receiving mechanical ventilation than the study group. 
Subject characteristics taken into consideration included age, gender, and preexisting 
health conditions. Other factors taken into consideration when analyzing the findings 
included treatment regimen, and delivery of treatment. Five of the ten studies were rated 
as high quality overall with respect to external validity. However, three of the five studies 
with high quality scores and overall good internal validity also had good generalizability. 
This included two studies which evaluated 0.12% CHX solutions [Bellissimo-Rodrigues 
et al. (114) and Scannapieco et al. (47)] and one study evaluating 0.2% chlorhexidine 
gluconate [(Ozcaka et al (118)]. 
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The category of 0.12% chlorhexidine solution presents the strongest evidence in 
Table 2. Seven of the studies included in this review used 0.12% chlorhexidine and, 
focused on patients 18 years of age and older admitted to the ICU with a prospective 
length of stay and who were at low to high risk for VAP. Each study had a specification 
on the number of times throughout a 24 hour period in which 0.12% chlorhexidine was 
applied to each subject. Three studies in this category focused on a low-risk population of 
cardiovascular surgery patients. These studies seemed to show conflicting results with 
respect to whether or not 0.12% CHX was significant in reducing the development of 
VAP. The most significant reduction in VAP, especially for patients undergoing cardiac 
surgery, was seen in DeRiso et al. with 69% reduction in total respiratory tract infections 
(112). In this study, 353 cardiac surgery subjects, who were admitted to a surgical ICU, 
were divided into two groups. A test group of 173 people who received a 0.12% 
chlorhexidine oral rinse twice a day and a control group of 180 subjects who received a 
placebo rinse. This study demonstrated that the use of the oral antiseptic chlorhexidine 
significantly reduced rates of nosocomial infection and VAP in a low-risk population of 
patients undergoing coronary artery bypass surgery (7,120). A prospective, randomized, 
case-controlled clinical trial conducted by Houston et al. tested the effectiveness of 
0.12% CHX gluconate oral rinse on 561 patients undergoing aortocoronary bypass or 
valve surgery patients, (experimental =270 and control = 291). The intervention involved 
oral care with 15mL of Peridex or Listerine™ preoperatively and postoperatively. Unlike 
Peridex, Listerine™ is a nonsubstantive agent that has properties similar to Peridex 
(0.12% CHX gluconate) in that it kills bacteria immediately upon application but does 
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not persist in tissues (6). Overall, use of chlorhexidine oral rinse reduced the total 
nosocomial respiratory infection rate and the use of nonprophylactic systemic antibiotics 
in patients who had heart surgery. Peridex oral rinse decreased microbial colonization of 
the respiratory tract and hospital-acquired pneumonia in patients undergoing open-heart 
surgery. However, the difference was not significant in patients intubated more than 24 
hours who had the highest degree of bacterial colonization (6). The results showed that 
the overall rate of hospital-acquired pneumonia was reduced by 52% but the reduction 
was not significant (4/270 vs. 9/291; P = (0.21) in patients treated with Peridex 
chlorhexidine gluconate when compared to patients treated with Listerine™ (8,26). 
Houston et al. compared chlorhexidine rinse to Listerine® and found no statistically 
significant difference in the pneumonia rate between the 2 groups (43). The final study 
that focused on cardiovascular patients was by Segers and coworkers. They focused on 
the efficacy of 0.12% CHX solution and 0.12% nasal ointment for patients preoperatively 
and postoperatively. The study included 991 patients who received CHX and 
nasopharynx decontamination (n = 500) or placebo (n = 491). All patients were older 
than 18 years of age and were scheduled to undergo sternotomy for cardiothoracic 
surgery. The treatment group received 10ml of oropharyngeal 0.12% CHX rinse and 
0.12% CHX nasal ointment 4 times a day until the nasogastric tube was removed. 
Usually the nasogastric tube was removed the day after surgery. The control group 
received 10ml of oropharyngeal rinse and nasal ointment placebos. Any lower respiratory 
tract infection (LRTI), such as pneumonia, occurring during a hospital stay or within 48 
hours after discharge was considered an infection related to a surgical procedure. They 
	  	  	  50   
found lower respiratory tract infections were less common in the chlorhexidine gluconate 
group, 9.3% compared to the placebo group, which was 15.8% (ARR, 6.5%; 95% CI, 
2.3%-10.7%; P = .002). An incidence of LRTI was found in 119 patients (12.5%), which 
achieved a relative risk reduction of more than 60% in patients decontaminated with 
chlorhexidine gluconate. Decontamination of the nasopharynx with chlorhexidine 
gluconate resulted in a clinically important reduction in LRTI. Significant reductions 
were found in nosocomial infections in patients undergoing cardiac surgery and treated 
with chlorhexidine gluconate. It is effective in decontamination of the nasopharynx and 
oropharynx, resulting in less LRTI. 
The other group of subjects evaluated in two other studies also using 0.12% CHX 
rinse focused on a particular population of surgical patients. However, these studies 
included a population of postoperative patients, whose clinical baseline characteristics 
and risks of nosocomial infections very different from those of a general medical ICU 
population. Genuit et al. implemented a weaning protocol (WP) along with the 0.12% 
CHX solution administered to 95 surgical subjects twice daily (113). Patients in the WP + 
CH group showed both a decreased incidence of pneumonia as well as a delay in the 
occurrence of VAP compared with the control group (113). Genuit et al. compared the 
early VAP phase WP group and control group and found that the risk of developing VAP 
increased significantly from 12.5% to > 45%. When CHX was added to the WP, there 
was only a moderate increased risk in VAP from 3.5% to 18%. A significant decrease 
was shown in the VAP rate for the WP + CHX group (21.0) with a 33% reduction 
compared with the control, p < 0.025) (113). The addition of oral care to a protocol of 
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weaning from mechanical ventilation led to a significant reduction of late-onset VAP (8). 
Grap utilized a block randomization scheme for 145 trauma patients requiring 
endotracheal intubation randomly assigned to the intervention or control group (116). 
Seventy percent of the patients were male, and 60% were white; their mean age was 42.4 
years (±18.2). The 74 patients in the control group received standard endotracheal 
intubation and oral care that did not include CHX. The 71 patients in the intervention 
group received one 5mL dose of 0.12% CHX solution applied with a swab to all areas of 
the oral cavity. The VAP Clinical Pulmonary Infection Score was used to measure the 
VAP development rate on study admission and at 48 and 72 hours after intubation. 
Subjects without pneumonia where classified as having a baseline of CPIS <6. After 48 
to 72 hours the intervention group had only 33% of their subjects with VAP whereas the 
control had 55.6%. A significant treatment effect was found on CPIS both from 
admission to 48 hours (P = 0.020) and to 72 hours (P = 0.027). An early, single 
application of CHX to the oral cavity significantly reduced CPIS and thus VAP in trauma 
patients. Since it is difficult to distinguish the pulmonary inflammation of sepsis from 
VAP, it may also be difficult to attribute all the differences in CPIS to the development of 
VAP alone.  
Scannapieco et al. is the only study out of the seven studies using 0.12% CHX 
oral rinse that compared two different CHX protocols with the control group and 
observed a 41% reduction in VAP between the experimental and placebo group. The 
study included a control group (49 patients) and two intervention groups receiving CHX 
0.12% either once (47 patients) or twice daily (50 patients). There was no statistically 
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significant difference when the two groups, one versus two applications of 0.12% CHX 
oral rinse were compared to each other with regard to the reduction of VAP development 
(47,118,121,122). Estimated reductions in colonization were 25% and 30% in the ‘twice-
daily’ and ‘once-daily’ groups, respectively. The number of Staphylococcus aureus 
colony-forming units, a well-known colonizing potential respiratory pathogen (PRP), in 
dental plaque was reduced in both intervention groups, but no significant reductions were 
observed in the total number of respiratory pathogens or incidence of VAP 
(47,118,121,122). Scannapieco et al. postulated that the standardized oral-care regime for 
this particular study used in the ICU was effective in reducing the number of organisms 
in dental plaque to a level where additional reductions by CHX were not detectable, or 
other factors such as suctioning could have reduced the effect of the CHX oral rinse 
(118). Scannapieco et al. reported that there were no significant differences between one 
or two applications of 0.12% CHX rinse with regard to the reduction of VAP 
development (47,118,121,122). Oral application of a 0.12% solution of chlorhexidine 
was effective in reducing the number of PRPs in dental plaque, but not superior to the 
placebo in preventing respiratory tract infection among ICU patients.  
A study by Bellissimo-Rodrigues et al. used a double-blind, randomized, placebo-
controlled trial comprising 194 participants admitted to the ICU with a prospective length 
of stay greater than 48 hours. The patients were divided into two randomized groups: 
those who received 15ml of 0.12% chlorhexidine (n=98) and those who received 15ml of 
placebo (n=96) three times a day throughout the duration of the patient’s stay in the ICU. 
Rates of ventilator-associated pneumonia per 1,000 ventilator-days were similar between 
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both experimental and control groups (22.6 vs. 22.3; P = .95). There was no report in 
improvement in the incidence of pneumonia, mortality or the overall incidence of 
respiratory tract infections between the two groups (114). The 0.12% CHX solution 
showed the preventive measure’s relative risk (RR) =1.00 (95% confidence interval [CI], 
0.63-1.60) after adjustment for sex, age, and LOS in the ICU. When analyzing the 
secondary endpoints, there was no significant difference in respiratory tract infection-free 
survival time, duration of mechanical ventilation, antimicrobial use either for respiratory 
infections or for any purpose, or LOS in the ICU. The data clearly indicated that oral 
application of a 0.12% solution of chlorhexidine was not superior to a placebo for the 
prevention of respiratory tract infection among ICU patients. Yet, for ICU patients, 
0.12% CHX oral solution would be enough to minimize oral and tracheal microbial 
proliferation. The results suggest that oral application of a 0.12% solution of 
chlorhexidine does not prevent respiratory tract infections in ICU patients, although it 
may retard their onset. 
Tantipong et al. used a stronger solution of CHX on patients in the ICU and 
medical wards. They used 2% chlorhexidine and measured the development of VAP and 
oropharyngeal colonization with Gram-negative bacilli (117). The study was conducted 
at Siriraj Hospital in Bangkok, Thailand. This study included all patients who underwent 
mechanical ventilation for more than 48 hours (117). The mean duration of mechanical 
ventilation was approximately 5 days, but only 43% of patients in the test group and 50% 
of patients in the control group received ventilation for more than 48 hours (117). 
Patients were randomized by sex into two groups: the chlorhexidine group (n=102) and 
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the normal saline group (n=105) (117). Each group received either 15ml of 2% 
chlorhexidine solution or 15ml of normal solution four times a day until the endotracheal 
tube was removed (117). The authors were unable to perform a double-blind study 
because the odor of chlorhexidine is very distinctive and could not be imitated (117,123). 
In order to avoid biases, the observer was unaware of how patients were assigned to each 
group. Many of the patients in the general medical ward were more stable than patients in 
the ICU, although they normally would have been kept in the ICU (117). Patients ended 
up in the general medical ward as a result of limited capacity in the ICU, which is 
sometimes the norm in developing counties (123). However the care of a patient who 
receives ventilation in the medical ward or ICU could not be compared with respect to 
regular protocols, parenteral antibiotic policy, and patient positioning (117). 
Approximately 60% of patients admitted to their study were adults who received 
ventilation in intensive care units (ICUs) (mainly surgical ICUs), whereas 40% received 
ventilation in general medical wards (117). Although use of chlorhexidine reduced the 
risk of VAP by approximately 55% in the overall population and among patients who 
received mechanical ventilation for more than 2 days, this reduction was not statistically 
significant, because both relative-risk (RR) calculations had large 95% confidence 
intervals (CIs) (RR, 0.43 [95% CI, 0.16–1.17] for study patients who received 
mechanical ventilation and oral decontamination (117). The Tantipong et al. study was 
not generalizable because it included patients who were mechanically ventilated ≤ 48 
hours (117). Efficacy was demonstrated by the incidence of VAP, 4.9% (5 of 102) and 
11.4% (12 of 105) for the CHX group and the normal saline group, respectively (117). 
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The study showed a significant (P = 0.04) reduction for the intervention group in the 
number of episodes of pneumonia per 1,000 ventilator-days, but this reduction was not 
statistically significant (P=0.06) when the authors evaluated only patients who received 
mechanical ventilation for more than 48 hours, which is an acceptable period for the 
diagnosis of VAP (11). They also showed that the nosocomial infection rate was 
decreased by as much as 65% in patients treated with chlorhexidine when compared with 
patients who received placebo (19). Along with the reduction in the incidence of VAP, 
2% CHX also decreased or delayed the rate of oropharyngeal colonization with potential 
respiratory pathogens (PRPs) such as Pseudomonas aeruginosa, Acinetobacter 
baumannii, and Klebsiella pneumoniae (117). These PRPs have the ability to cause upper 
and lower respiratory tract infections such as VAP. Irritation of the oral mucosa was 
observed in ten (9.8%) of the patients in the chlorhexidine group and in one (0.9%) of the 
patients in the normal saline group (P=0.001) (117). Oropharyngeal colonization with 
Gram-negative bacilli, which are PRPs, was either reduced or delayed in the 
chlorhexidine group (117). 
 Two studies focused on 0.2 % chlorhexidine which is not as strong as the 2% used 
in Tantipong et al. study (117-119). Panchabhai and colleagues reported the results of a 
randomized trial of oropharyngeal cleansing with a 0.2% chlorhexidine solution twice 
daily vs. a 0.01% potassium permanganate solution as a control in patients who had been 
admitted to a combined medical-neurologic ICU in a 1,800-bed tertiary care teaching 
hospital in Mumbai, India, during the 8-month study period. There were 512 patients 
introduced to concealed randomization with an open label design. The 512 were 
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randomized to either the chlorhexidine group (n=250) or the control group (n=262). 
Out of the large randomized group only approximately one third of patients enrolled in 
the trial were actually intubated and receiving mechanical ventilation. The CHX group 
received oropharyngeal cleansing with a 0.2% chlorhexidine solution twice daily vs. a 
0.01% potassium permanganate solution twice daily tested for the control group. Out of 
471 subjects who completed the study protocol, oropharyngeal disinfection with a 0.2% 
CHX solution in critically ill patients did not decrease the incidence of pneumonia. The 
incidence of nosocomial pneumonia was found in 16 of 224 subjects (7.1%) in the 
chlorhexidine group and 19 of 247 subjects (7.7%) in the control group (p = 0.82; relative 
risk, 0.93; 95% confidence interval, 0.49 to 1.76). As expected, among mechanically-
ventilated patients, the rates of pneumonia were considerably higher (chlorhexidine 
group, 15.9%; potassium permanganate group, 18.1%), but the sample sizes may not 
have been large enough to detect a significant difference in VAP rates between these 
groups, given the relatively low number of intubated patients (10). The incidence of VAP 
in patients in the study during the 6-month period, including three months of patients 
before the start of the study and three months after the study, was significantly higher. 
During this non-study period, nosocomial pneumonia developed in 21.7% subjects, 
which was significantly higher than the 7.4% incidence of nosocomial pneumonia 
observed during the study period (p< 0.001; relative risk, 0.34; 95% confidence interval 
0.24 to 0.49). Panchabai et al. showed a decrease in the incidence of nosocomial 
pneumonia for both study groups when oral hygiene was implemented, however 
oropharyngeal cleansing with 0.2% chlorhexidine solution was not superior to oral 
	  	  	  57   
cleansing with the control solution (119). Nosocomial pneumonia also developed in 
fewer subjects (35 of 471 subjects [7.4%]) than in the three months preceding and 
following the study (98 of 452 subjects [21.7%]; p < 0.001; relative risk, 0.34; 95% 
confidence interval, 0.24 to 0.49). Oropharyngeal cleansing with 0.2% chlorhexidine 
solution was not superior to oral cleansing with the control solution. However, the 
decreased incidence of nosocomial pneumonia during the study period suggests a 
possible benefit of meticulous oral hygiene in ICU patients. 
Özçaka et al. studied 61 dentate patients in a respiratory ICU, scheduled for 
mechanical ventilation for at least 48 hours. The randomized double-blind, controlled 
study provided oral care to these 61 patients randomized to a control group or a treatment 
group receiving oral swabs of 30ml of normal saline or 30ml of 0.2% CHX, respectively. 
In order to quantitatively determine whether or not patients developed VAP or PRPs, 
specimens were obtained from the lower respiratory tract. Specimens were obtained at 
each sampling timepoint, e.g. on admission and on day seven of intubation, or when 
suspected VAP occurred using a minibronchoalveolar lavage (mini-BAL). A 
microbiological analysis was conducted on the lower respiratory tract specimens during 
admission and when VAP was suspected. Colonies were quantified using standard culture 
techniques to identify pathogens. The samples from the mini-BAL included potential 
respiratory pathogens (S. aureus, P. aeruginosa, Acinetobacter species, and the enteric 
species Klebsiella pneumoniae, Serratia marcescens, Escherichia species, Proteus 
mirabilis and Escherichia coli). Acinetobacter baumannii was the most common 
pathogen (64.7%) of all species identified. The results from the specimens identified 
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ventilator-associated pneumonia development in 34/61 patients (55.7%) within 6.8 days. 
VAP development rate was significantly higher in the control group than in the CHX 
group (68.8% vs. 41.4%, respectively; p = 0.03). The rate of VAP occurrence in the 
control group was significantly higher than in the CHX group with an odds ratio of 3.12 
(95% confidence interval = 1.09-8.91, p = 0.03). Twenty-two patients (68.8%) in the 
control group and 12 patients (41.4%) in the CHX group were diagnosed with VAP. 
There were no significant differences with regards to duration of VAP development 
between the CHX and control groups.   
In conclusion, within the limits of the present study, it is suggested that oral care 
in ICU patients which includes application of 0.2% CHX four times a day, reduces the 
risk of VAP development. This means that the association between nosocomial 
pneumonia may be related to oral hygiene and not related to periodontal systemic disease 
interactions. Swabbing four times daily with 0.2% CHX reduced significantly the number 
of patients with VAP compared with the control. Findings of this systematic review 
strongly support its use in ICUs and indeed the importance of adequate oral hygiene in 
preventing medical complications. 
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DISCUSSION 
 
Modulation of oropharyngeal colonization by the use of oral chlorhexidine has 
prevented ICU-acquired HAP in selected patient populations such as those undergoing 
coronary bypass grafting, but its routine use is not recommended until more data become 
available (7). Oral care is supported by previous studies and believed to reduce the risk of 
VAP development in mechanically-ventilated patients (118). This review looked at the 
best intervention performed in hospital environments to evaluate the efficacy of 
chlorhexidine in reducing the incidence of VAP. 
This systematic review of clinical trials presents a mixture of evidence for 
effectiveness of chlorhexidine gluconate oral rinse use on high-risk adult mechanical 
ventilator patients. All authors have substantiated the need to standardize oral care for a 
variety of reasons, the most compelling of which is to prevent or lower VAP rates in 
mechanically-ventilated patients (63). As identified in Table 4, three types of CHX oral 
rinse were identified. For the various modes of CHX, there were studies that supported 
CHX oral rinse and were well executed and reported. The studies in this review revealed 
conflicting findings for the use of CHX oral rinse in preventing VAP. 
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Table 4:  Risk Ratio 
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Studies included in the final review both supported and did not support the use of CHX 
oral rinse. Four out of ten studies evaluating CHX rinses had an overall quality rating of 
good. Two studies focused on 0.2 % chlorhexidine which is not as strong as the 2% used 
in Tantipong et al. study (117-119). Ozcaka et al. and Panchabhai et al, applied the 0.2 % 
chlorhexidine from two to four times daily (118,119). Ozcaka et al, demonstrated a rate 
of VAP occurrence in the control group that was significantly higher than in the CHX 
group (118). From Scannapieco and colleagues’ study we can conclude that twice daily is 
not necessarily better than once daily, but maybe a four times daily regimen with 2% 
instead of 0.12% CHX does make a difference (12). In a study (24) of patients 
undergoing cardiac surgery, use of chlorhexidine decreased the incidence of VAP by 
decreasing colonization of VAP by bacteria that can cause VAP (31). Bellissimo-
Rodrigues et al. showed that 0.12% CHX was not superior to the placebo and did not 
prevent respiratory tract infections. Three other studies showed a reduction in VAP but 
were not significant enough to predict that CHX oral rinse will prevent VAP. Recently, 
the antiseptic chlorhexidine gluconate (0.12%) was used successfully as a perioperative 
oral rinse to decrease the overall incidence and demonstrated prevention of nosocomial 
respiratory tract infections in patients who underwent cardiac surgery (18). However, its 
use for preventing healthcare associated pneumonia in other groups of patients at high 
risk for this infection has not been evaluated (43). Three out of the four studies found the 
CHX oral rinse to be effective in preventing VAP. Chlorhexidine at 0.1-0.2 is 
recommended as the most effective antiplaque agent (65). 
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Adult mechanically-intubated patients considered to be at high-risk for VAP were 
subcategorized as low to high-risk patients based on the reason for mechanical 
ventilation. For instance, a patient intubated for a surgical procedure would be considered 
low risk for developing VAP whereas a patient intubated due to respiratory failure is 
considered a high-risk patient for VAP. Surgical procedure patients are less likely to stay 
on the ventilator for more than a day, which reduces their chances for developing VAP. 
In studies of cardiovascular, surgical, and trauma patients who were mechanically 
ventilated, a reduction in VAP was observed when CHX was used. Selected studies 
supporting the use of CHX in reducing VAP did not always produce statistically 
significant results. Some studies did produce results in reduction of oral colonization of 
PRPs and incidence of VAP. However other studies also showed a reduction of PRPs 
when using CHX yet VAP rates were still high. Then there are investigators in other 
selected studies reporting oral care with CHX to be effective in combating PRPs but 
without influence on VAP rates (124). These trials have yielded conflicting results.  
Three of the ten studies included subjects who were receiving some type of 
cardiothoracic surgery, whether it was coronary artery bypass grafting (CABG) and/or 
valve replacement (6,112,115). Considering the specific patient population with low 
risks, CHX oral rinse as a preventive measure for VAP has been evaluated before in two 
trials among cardiac-surgical patients (21,120,125). There are, however, important 
differences between elective surgery and the emergency surgery populations that 
influence oral care strategies. Elective surgery subjects are likely to have different 
comorbidities and better physiologic status at the time of intubation than emergently 
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intubated patients. However, cardiac surgery patients who have elective surgery most 
likely have different comorbidity conditions and better physiological status at the time of 
intubation than do patients in the general adult ICU population. Studies in patients having 
elective cardiac surgery focused broadly on nosocomial infection (including surgical 
infection and tracheobronchitis) rather than on VAP (126). 
Current evidence does not conclusively support the routine use of chlorhexidine 
in mechanically-ventilated patients other than those patients who have just undergone 
cardiac surgery. Some studies are not generalizable and included subjects who were at 
high-risk and could not be extubated within 24 hours. As patients are receiving 
mechanical ventilation for an extended period of time i.e., longer than 24 hours, this 
allows for opportunistic pathogens to multiply and colonize. Some of these studies 
included those subjects undergoing cardiothoracic surgery (6,47,112,114). The oral care 
recommendations are general, and evidence available when the guidelines were updated 
was insufficient for making a recommendation for use of chlorhexidine in the general 
ICU population (126). Oral decontamination with chlorhexidine in different 
concentrations is also considered a strategy for reducing the incidence of VAP (118). The 
meta-analysis by Pineda et al. included only four randomized control trials (RCTs) and 
was unable to demonstrate a significant reduction by using chlorhexidine solution in 
various concentrations for oral care (127). The efficacy of CHX is difficult to 
discriminate between control and experimental groups when other prophylactic measures 
are used in addition to CHX. The question that arises is how reliable are these studies that 
state that CHX reduces VAP. For instance, along with 0.12% CHX solution, the subjects 
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in the Segers et al. study used 0.12% CHX nose ointment in both nostrils. Patients in the 
control group received more nonprophylactic antimicrobials. Therefore it is not possible 
to determine if there is a difference in the mouth or the nose decontamination in reducing 
VAP. In De Riso et al., all patients received standard oral care. It is difficult to 
distinguish the role of the chlorhexidine in reducing VAP when the surgical patients have 
perioperative prophylaxis with parenteral antibiotics. It is not possible to discern if the 
reduction in VAP is due to the CHX or the other prophylactic measures. 
No recommendation can be made for the routine use of an oral chlorhexidine 
rinse for the prevention of healthcare-associated pneumonia in all postoperative or 
critically ill patients or other patients at high risk for pneumonia (43). However, these 
studies included a population of postoperative patients, whose clinical baseline 
characteristics and risks of nosocomial infections were very different from those of a 
medical ICU population (8). Recommendations for patients having elective cardiac 
surgery include the use of chlorhexidine during the perioperative period and are based on 
the results of several studies in which patients began using chlorhexidine before hospital 
admission for elective cardiac surgery and chlorhexidine use was continued throughout 
the hospital stay. Not only are these studies not generalizable, but they also have 
demonstrated inconsistency of CHX effectiveness among mechanically-ventilated 
patients. Studies like Tantipong et al. are more generalizable since they included patients 
who were intubated more than 48 hours (117). The Scannapieco et al. study was of good 
quality but not generalizable because it included only white male subjects.   
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From this review, oral care performed regularly with an antiseptic solution is of 
high importance regardless of the optimal frequency and concentration of the solution 
(15). Regimens and concentrations, and dosing frequencies varied among the studies 
evaluated in this review and sometimes were not carefully described (12). For example, 
one study used 0.12% CHX twice daily to 2% CHX four times a day (12). In addition, 
patient populations varied widely from mixed ICU populations [9,12] to surgical ICU 
patients [10] and patients undergoing cardiac surgery [8,11,13] (12).  
This safe and inexpensive disinfectant is effective in decontaminating the 
nasopharynx and oropharynx, resulting in less LRTI, and should be considered in the 
preoperative preparation of a patient undergoing cardiac surgery. Any of the at-risk 
patients excluded from this study, would be of interest for further research to compare 
chlorhexidine gluconate with a more selective decontamination of the digestive tract 
protocol, which uses antibiotics and has an increased risk of promoting microbial 
resistance. What we need now are well-designed and adequately powered studies to 
evaluate the effects of CHX on length of ICU stay and survival. If these effects were 
demonstrated, chlorhexidine selective oropharyngeal decontamination would offer a very 
cheap and (ecologically) safe infection prevention measure in patient populations 
increasingly suffering from lower respiratory tract infections (12). 
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